XBI is trading 3.14% up today at $152.50, with the move appearing tied to biotech-sector strength rather than an ETF-specific catalyst. - Merck KGaA’s announced acquisition of Silence Therapeutics has drawn attention to biotech dealmaking. - Disc Medicine’s positive Phase 3 results have highlighted clinical progress. - The broad-market picture is mixed, pointing more strongly to sector-specific sentiment than an overall market lift.